[go: up one dir, main page]

FI973323L - Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo - Google Patents

Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo Download PDF

Info

Publication number
FI973323L
FI973323L FI973323A FI973323A FI973323L FI 973323 L FI973323 L FI 973323L FI 973323 A FI973323 A FI 973323A FI 973323 A FI973323 A FI 973323A FI 973323 L FI973323 L FI 973323L
Authority
FI
Finland
Prior art keywords
transfection
vivo
expression
drug combination
exogenous molecules
Prior art date
Application number
FI973323A
Other languages
English (en)
Swedish (sv)
Other versions
FI973323A0 (fi
FI119176B (fi
Inventor
Jean-Francois Bach
Lucienne Chatenoud
Hedi Haddada
Martin Lee
Michel Perricaudet
Michelle Webb
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of FI973323A0 publication Critical patent/FI973323A0/fi
Publication of FI973323L publication Critical patent/FI973323L/fi
Application granted granted Critical
Publication of FI119176B publication Critical patent/FI119176B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI973323A 1995-02-14 1997-08-13 Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo FI119176B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9501662A FR2730411B1 (fr) 1995-02-14 1995-02-14 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
FR9501662 1995-02-14
FR9600218 1996-01-10
PCT/FR1996/000218 WO1996025177A1 (fr) 1995-02-14 1996-02-12 Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes

Publications (3)

Publication Number Publication Date
FI973323A0 FI973323A0 (fi) 1997-08-13
FI973323L true FI973323L (fi) 1997-08-13
FI119176B FI119176B (fi) 2008-08-29

Family

ID=9476106

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973323A FI119176B (fi) 1995-02-14 1997-08-13 Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo

Country Status (23)

Country Link
US (2) US20030004091A1 (fi)
EP (1) EP0809516B1 (fi)
JP (1) JPH11500430A (fi)
KR (1) KR100402540B1 (fi)
AT (1) ATE204481T1 (fi)
AU (1) AU717218B2 (fi)
BR (1) BR9607310A (fi)
CA (1) CA2211039C (fi)
CZ (1) CZ258197A3 (fi)
DE (1) DE69614668T2 (fi)
DK (1) DK0809516T3 (fi)
ES (1) ES2163612T3 (fi)
FI (1) FI119176B (fi)
FR (1) FR2730411B1 (fi)
GR (1) GR3036438T3 (fi)
HU (1) HU222991B1 (fi)
IL (1) IL117116A0 (fi)
MX (1) MX9706017A (fi)
NO (1) NO320072B1 (fi)
PT (1) PT809516E (fi)
SK (1) SK282235B6 (fi)
WO (1) WO1996025177A1 (fi)
ZA (1) ZA961161B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1998008539A1 (en) * 1996-08-26 1998-03-05 Chiron Corporation Postinfection human immunodeficiency virus (hiv) vaccination therapy
US6525029B1 (en) 1997-10-30 2003-02-25 Cornell Research Foundation, Inc. Method of inhibiting and immune response to a recombinant vector
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1141313A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
WO2000074688A1 (en) * 1999-06-08 2000-12-14 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
BR0111158A (pt) 2000-05-12 2004-04-06 Genzyme Corp Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
EP1432447A2 (en) * 2001-09-27 2004-06-30 The Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
AU2003291143A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
WO2008013918A2 (en) * 2006-07-26 2008-01-31 Myelin Repair Foundation, Inc. Cell cycle regulation and differentiation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016065A1 (en) * 1992-12-31 1994-07-21 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells
WO1994016080A1 (en) * 1993-01-08 1994-07-21 Exemplar Corporation An in vitro/in vivo method for identifying anti-neoplastic drugs
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus

Also Published As

Publication number Publication date
NO973724D0 (no) 1997-08-13
CA2211039C (fr) 2011-12-06
ES2163612T3 (es) 2002-02-01
HU222991B1 (hu) 2004-01-28
EP0809516A1 (fr) 1997-12-03
US20040265276A1 (en) 2004-12-30
CZ258197A3 (en) 1997-11-12
FI973323A0 (fi) 1997-08-13
CA2211039A1 (fr) 1996-08-22
SK110897A3 (en) 1998-01-14
EP0809516B1 (fr) 2001-08-22
NO320072B1 (no) 2005-10-17
BR9607310A (pt) 1997-11-25
ATE204481T1 (de) 2001-09-15
US20030004091A1 (en) 2003-01-02
HUP9800635A3 (en) 2000-12-28
AU4723896A (en) 1996-09-04
MX9706017A (es) 1997-11-29
FR2730411B1 (fr) 1997-03-28
DE69614668D1 (de) 2001-09-27
KR19980702199A (ko) 1998-07-15
PT809516E (pt) 2002-02-28
GR3036438T3 (en) 2001-11-30
FI119176B (fi) 2008-08-29
NO973724L (no) 1997-08-13
IL117116A0 (en) 1996-06-18
DK0809516T3 (da) 2001-12-17
ZA961161B (en) 1996-08-07
HUP9800635A2 (hu) 1998-07-28
WO1996025177A1 (fr) 1996-08-22
FR2730411A1 (fr) 1996-08-14
SK282235B6 (sk) 2001-12-03
JPH11500430A (ja) 1999-01-12
DE69614668T2 (de) 2002-06-27
AU717218B2 (en) 2000-03-23
KR100402540B1 (ko) 2004-05-07

Similar Documents

Publication Publication Date Title
FI973323L (fi) Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo
FI973048A7 (fi) Menetelmät ja koostumukset hydrofiilisten molekyylien lipidisoimiseksi
ATE218547T1 (de) Acylierte derivate von melatonin und dessen analoge als arzneimittel
FI973467A7 (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
FI963513A7 (fi) Geenien rinnakkainen ilmentäminen in vivo
FI980561A7 (fi) Pneumokokkaalliset geenit, niiden osat, ilmentämistuotteet niistä ja s ellaisten geenien, osien ja tuotteiden käytöt
FI964172A7 (fi) Geenin ilmentymisjärjestelmä in vivo
FI970967L (fi) Heterosyklinen johdannainen ja lääkeaine
ATE221531T1 (de) Kristallmodifikation des cdch, verfahren zu dessen herstellung und diese enthaltende pharmazeutische zubereitungen
FI953898A0 (fi) Glysiiniamidijohdannaisia, menetelmiä niiden valmistamiseksi ja niitä sisältäviä lääkeaineita
ATE224910T1 (de) Derivate von dolestatin, deren herstellung und verwendung
DE69620270D1 (de) Backfett und dessen Verwendung
EE9600139A (et) Farmatseutilised preparaadid ja ravimid endoteelsete düsfunktsioonide vältimiseks ja raviks
FI971168L (fi) Keskushermoston toiminnan ja häiriön in vitro -mallit
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
FI950289L (fi) Menetelmä ja sovitelma anesteetin höyrystämisen yhteydessä
FI964482L (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
EE04371B1 (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
DZ2078A1 (fr) Nouveaux médicaments hormonaux et leur utilisationpour la correction des carences estrogéniques.
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
EE9700177A (et) Parendatud omadustega aprotiniini derivaadid, nende kasutamine ravimite tootmiseks ja aprotiniini derivaate sisaldavad ravimid
NO973980D0 (no) Imiadazolderivater og medisinsk preparat
EE03687B1 (et) Furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
FR2787447B1 (fr) Nouveaux derives de melatonine et medicament comprenant de tels derives
ATE229812T1 (de) Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119176

Country of ref document: FI

MM Patent lapsed